Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 17/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 17/20 | 0.53 |
| ▸ | HRH2 | P25021 | 4/20 | 0.52 |
| ▸ | HTR2C | P28335 | 4/20 | 0.52 |
| ▸ | HRH1 | P35367 | 4/20 | 0.52 |
| ▸ | HTR1E | P28566 | 3/20 | 0.52 |
| ▸ | HTR1A | P08908 | 3/20 | 0.52 |
| ▸ | HTR2A | P28223 | 3/20 | 0.52 |
| ▸ | HTR2B | P41595 | 3/20 | 0.52 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.52 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.52 |
| ▸ | HTR1B | P28222 | 2/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.47 |
| ▸ | DRD3 | P35462 | 2/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31607740 | 0.92 | TMEM97 (0.53) | TMEM97SIGMAR1HRH2HTR2CHRH1 | |
| SCHEMBL1655581 | 0.82 | NOTUM (0.41) | HRH3 | |
| SCHEMBL10702359 | 0.82 | SMN1; SMN2 (0.42) | TMEM97SIGMAR1HRH2HTR2CHRH1 | |
| SCHEMBL977882 | 0.81 | ADORA1 (0.48) | — | |
| SCHEMBL977652 | 0.81 | MEN1 (0.52) | — | |
| SCHEMBL30458160 | 0.78 | TMEM97 (0.54) | TMEM97SIGMAR1HRH2HTR2CHRH1 | |
| SCHEMBL30458157 | 0.78 | TMEM97 (0.54) | TMEM97SIGMAR1HRH2HTR2CHRH1 | |
| SCHEMBL7075795 | 0.77 | KDR (0.49) | TMEM97SIGMAR1HRH2HTR2CHRH1 | |
| SCHEMBL4399188 | 0.77 | TMEM97 (0.49) | TMEM97SIGMAR1HRH2HTR2CHRH1 | |
| SCHEMBL3441575 | 0.76 | TMEM97 (0.52) | TMEM97SIGMAR1HRH2HTR2CHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240409542-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2024-12-12 | — | — | US | disclosed |
| EP-4408845-A1 | NOVEL COMPOUNDS | Sitryx Therapeutics Limited (GB) | 2024-08-07 | — | — | EP | disclosed |
| WO-2023052783-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2023-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240409542-A1 | NOVEL COMPOUNDS | CD47, GPR119, LRBA | TMEM97 4352/4885SIGMAR1 3984/4885HRH2 3171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.